European SPC filing strategy protects valuable IP exclusivity for pharma giant

Summary

As the foundation of AstraZeneca’s respiratory biologics portfolio, targeting the underlying causes of respiratory illnesses, Fasenra® (benralizumab) is a crucial product for this multinational client. This breakthrough treatment for eosinophilic asthma was AstraZeneca’s first biologic product to be approved in Europe.

Our specialist team managed the supplementary protection certificate (SPC) filing strategy across Europe, successfully securing the extension of AstraZeneca’s exclusivity in the European market.

Value delivered

The SPC portfolio is vital as it underpins AstraZeneca’s IP exclusivity for this drug for an additional five years beyond patent expiry in April 2020, thereby staving off market entry by competitors. 

This work underlines the expertise of our biotech group in devising appropriate SPC filing strategies and prosecuting them successfully in national patent offices around Europe, providing valuable protection for biologic medicines.